AbbVie Stock: Safe to buy or not?
AbbVie Inc. (NYSE: ABBV) is a relatively new biopharmaceutical company of the United States and its foundation was laid in the year 2013. The company has had fairly well performance and has given profits to the shareholders who have invested in this firm. The company is doing well and is going at a steady pace. The stock of this company comes with a dividend. The investors have to figure out between the dividend stocks since these are associated with the risk of increment or decrement of the dividend with time. An increase of dividend is always welcome while a reduction of the dividend brings loss in the investment. AbbVie Inc. (NYSE: ABBV) Stock analysis 52 Week Range: $62.55 - $113.41 Average Volume: 8,361,700 Market Capital: $197.326B Forward Dividend and Yield: 20 (4.71%) The pricing of the stock is moderate and the dividend is also high. The dividend has shown an increase and therefore, the stock becomes a less risky dividend stock with a higher probability of returning profits to the investors. AbbVie and Humira: What’s in for the Future? Humira being the consistently best-selling drug of the company overshadows the other products sometimes but now the other drugs, which are also highly effective against the respective diseases they are used to treat. Humira is however a very important drug and it is not sure whether a new drug can replace this drug because it is highly reliable. This doubt is there in the minds of the investors. If we consider…